Research Paper Advance Articles

Cyclin L1 participates in Adriamycin resistance and progression of osteosarcoma via PI3K/AKT-mTOR pathway

class="figure-viewer-img"

Figure 7. PI3K/AKT-mTOR pathway participated in the development and ADM-resistance. (A) The PI3K-Akt and mTOR were significantly enriched in OS patients with high CCNL1 levels by GSEA analysis. (B) Western blot results of the p-AKT and AKT in HOS/ADM and 143B/ADM cells. (C) Western blot results of the AKT (p-AKT), mTOR (p-mTOR), MRP1, Survivin, and MMP2 (with or without BKM120). (D) MTT assay results of the viability of HOS/ADM (143B/ADM) cells with BKM120. *P < 0.05, vs. the DMSO group. (E) Wound-healing assay of HOS/ADM and 143B/ADM cells at 0 h, 24 h (with or without BKM120). Bar = 200 μm. (F) The rate of tunnel-positive cells increased in the BKM120 group in comparison to the DMSO group exposing to ADM, Bar = 200 μm.